Minerva Neurosciences Inc Dossier
Qualitative Analysis
Business overview
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary product candidates to treat central nervous system (CNS) diseases. The company's lead product candidate is roluperidone (MIN-101), an investigational monotherapy designed to treat the negative symptoms of schizophrenia, such as avolition, anhedonia, and social withdrawal. Negative symptoms represent a profound unmet medical need with no currently FDA-approved treatments. Minerva's pipeline also includes seltorexant (MIN-202), for which future royalty rights were sold to Royalty Pharma while Janssen continues Phase 3 development.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Initiation and conduct of a global confirmatory Phase 3 clinical trial of roluperidone (64 mg) as a monotherapy for the treatment of negative symptoms of schizophrenia, incorporating an extended 52-week relapse assessment phase as requested by the FDA.
Expected impact: Establish safety and efficacy data required for FDA NDA resubmission and potential commercial launch in the U.S.
Establishment of an at-the-market stock offering program allowing the company to issue and sell shares of common stock from time to time up to an aggregate offering price of $75.0 million through Leerink Partners LLC.
Expected impact: Provides flexible, opportunistic access to capital to support ongoing clinical development, working capital, and general corporate purposes.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Mind-NRG Sarl, a Swiss pre-clinical-stage biopharmaceutical company, to obtain exclusive global rights to develop and commercialize MIN-301, a clinical candidate for the treatment of Parkinson's disease.
Financial impact: Expanded the company's clinical-stage pipeline into Parkinson's disease therapeutics.
Strategic Partnerships
Minerva originally co-developed seltorexant (MIN-202) with Janssen. In July 2020, Minerva exercised its right to opt out of the agreement, eliminating all future clinical development and financial obligations while retaining a mid-single-digit royalty stream on future worldwide sales of seltorexant across all indications.
Terms: Mid-single-digit royalties on worldwide sales of seltorexant payable to Minerva, with zero ongoing funding obligations.